D Herlyn1, R Somasundaram, J Zaloudik
1Wistar Institute, Philadelphia, PA 19104, USA.
Recombinant colorectal cancer (CRC) antigen CO17-1A/GA733 shows promise as a vaccine. Preclinical studies indicate it elicits stronger immune responses than anti-idiotypic antibodies, suggesting potential for CRC patient treatment.
You might also read
Articles linked to this work by shared authors, journal, and citation graph.
Area of Science:
Background:
Purpose of the Study:
Main Methods:
Main Results:
Conclusions: